Truvestments Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Truvestments Capital’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$564	Hold	265	–	–	﹤0.01%	1069
2026 Q1	$448	Hold	265	–	–	﹤0.01%	1094
2025 Q4	$1.37K	Hold	265	–	–	﹤0.01%	907
2025 Q3	$1.38K	Hold	265	–	–	﹤0.01%	941
2025 Q2	$1.01K	Hold	265	–	–	﹤0.01%	879
2025 Q1	$1.52K	Hold	265	–	–	﹤0.01%	898
2024 Q4	$1.32K	Hold	265	–	–	﹤0.01%	896
2024 Q3	$1.43K	Buy	+265	New	+$1.26K	﹤0.01%	829
2024 Q2	–	Sell	-265	Closed	-$867	–	238
2024 Q1	$867	Hold	265	–	–	﹤0.01%	657
2023 Q4	$930	Hold	265	–	–	﹤0.01%	714
2023 Q3	$1.77K	Hold	265	–	–	﹤0.01%	597
2023 Q2	$2.22K	Hold	265	–	–	﹤0.01%	595
2023 Q1	$2.63K	Sell	265 -664	-71%	-$4.69K	﹤0.01%	560
2022 Q4	$6.47K	Hold	929	–	–	﹤0.01%	513
2022 Q3	$5K	Hold	929	–	–	﹤0.01%	463
2022 Q2	$4K	Buy	+929	New	+$3.19K	﹤0.01%	489
2022 Q1	–	Sell	-419	Closed	-$2K	–	194
2021 Q4	$2K	Hold	419	–	–	﹤0.01%	544
2021 Q3	$4K	Hold	419	–	–	﹤0.01%	464
2021 Q2	$5K	Hold	419	–	–	﹤0.01%	451
2021 Q1	$5K	Sell	419 -114	-21%	-$1.31K	﹤0.01%	516
2020 Q4	$3K	Buy	+533	New	+$3.74K	﹤0.01%	522
2020 Q3	–	Sell	-533	Closed	-$2K	–	322
2020 Q2	$2K	Buy	+533	New	+$1.95K	﹤0.01%	502
2019 Q4	–	Sell	-936	Closed	-$5K	–	154
2019 Q3	$5K	Sell	936 -54	-5%	-$291	﹤0.01%	564
2019 Q2	$6K	Hold	990	–	–	﹤0.01%	588
2019 Q1	$9K	Buy	+990	New	+$8.41K	0.01%	527
2018 Q3	$15K	Buy	+1,065	New	+$8.64K	0.01%	564

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Truvestments Capital's ALDX Position: Q2 2026 in Review

Truvestments Capital held its Aldeyra Therapeutics (ALDX) position steady in Q2 2026 at 265 shares worth $564. The position accounts for ﹤0.01% of the portfolio, ranked #1069.

Truvestments Capital first reported a position in ALDX in Q3 2018 and has held it in 26 quarters since. The position peaked at $15K in Q3 2018. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Truvestments Capital held 265 shares of Aldeyra Therapeutics worth $564 as of Q2 2026.
Truvestments Capital left its Aldeyra Therapeutics share count unchanged in Q2 2026.
Aldeyra Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #1069 holding.
Truvestments Capital first reported a position in Aldeyra Therapeutics in Q3 2018 and has held it in 26 quarters since.
Truvestments Capital's Aldeyra Therapeutics position peaked at $15K in Q3 2018.
107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.